Sepsis is one of the country’s most urgent systemic health threats. Each year, more than 1.5 million people in the U.S. get sepsis. Sepsis kills a quarter-million Americans each year. Sepsis can occur when a trauma or an infection – often caused by a superbug or drug-resistant bacteria in the skin, lungs or urinary tract – triggers a chain reaction throughout the body. This is a cause for daily concern, but would be even more alarming in the aftermath of a Chemical, Biological, Radiological, or Nuclear (CBRN) event – those who survive the initial assault are at high risk of developing sepsis. Without timely recognition and treatment, it can rapidly cause tissue damage, organ failure, and death. One in three patients who die in a hospital have sepsis. Read more about sepsis.
Infections in the lungs (pneumonia), kidney (urinary tract infection), skin, and gut are often associated with sepsis. Bacteria that cause infections that develop into sepsis include Staphylococcus aureus (staph), Escherichia coli (E. coli), and some types of Streptococcus.
Anyone can get sepsis.
DRIVe is seeking bold solutions. These include innovations focused on:
Too often, people do not receive adequate and timely treatment for infectious diseases like influenza. We either do not seek care, or do so many days late, leading to severe illness, and transmission of infectious agents within the household, at the workplace.
Early Notification to Act, Control, and Treat (ENACT) will disrupt the traditional clinical care paradigm of healthcare being provided outside of the home (within a physician’s office, urgent care center, or hospital). The ENACT program will rapidly leverage the power of transformational technologies to empower individuals to be aware of their own health status and to take action. ENACT leverages advanced data analytics and algorithms coupled with innovative detection modalities to accurately and quickly diagnose patients who have been exposed to pathogens and prognosticate outcomes. ENACT will close the gap between diagnosis and treatment by utilizing the power of telemedicine to bring clinical care into the home. The de-identified data from these individual signals will create real-time information for public health officials about outbreaks in communities.
DRIVe aims to empower people; to give them a greater role in their health outcomes. We will develop biological, biometric, behavioral, and physiological technologies and approaches to identify threats and challenges and put in place systems to mitigate the harm. Better ways to detect threats, point-of-use indicators, biological and physiological sensing technologies – these are the types of solutions that can mean the difference between life and death.
Partnering possibilities could include non-dilutive funding and/or dilutive funding through DRIVe Launch or DRIVe Ventures.More information on partnering possibilities
DRIVe will seek a limited number of additional extremely bold, radical, and disruptive innovative solutions that will have the ability to transform health security. These include – but are not limited to – creating universal treatment options for broad classes of pathogens, ensuring access to life-saving medical countermeasures, and transforming medical countermeasure development by eradicating animal testing. For more information on these additional impact areas, see the DRIVe EZ Broad Agency Announcement.